Home > Insider Trading > Filing (0000899243-18-030927)

Filing Details

Accession Number:: 0000899243-18-030927
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2018-12-13 18:13:58
Reporting Period:: 2018-12-06

Accepted Time:: 2018-12-13 18:13:58
Original Submission Date:: 2018-12-10
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1731831	Eidos Therapeutics Inc.	EIDX	Pharmaceutical Preparations (2834)	463733671

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1743881	Bridgebio Pharma Llc	421 Kipling St. Palo Alto CA 94301		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-12-06	38,970	$13.34	22,507,473	No	4	P	Direct
Common Stock	Acquisiton	2018-12-07	36,314	$13.94	22,543,787	No	4	P	Direct
Common Stock	Acquisiton	2018-12-07	4,860	$14.36	22,548,647	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Footnotes

All shares of the Issuer's Common Stock, par value $0.001 per share (the "Common Stock") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the "IPO"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock;
(Continued from footnote 1) (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO.
Represents the weighted average purchase price of the shares purchased ranging from $12.79 to $13.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
Represents the weighted average purchase price of the shares purchased ranging from $13.33 to $14.32 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
Represents the weighted average purchase price of the shares purchased ranging from $13.34 to $14.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
Due to a clerical error, the Form 4 filed on December 10, 2018 inadvertently reflected a transaction code of "S" instead of "P" to reflect that the securities were purchased, and the footnote contained in the Form 4 inadvertently referred to the reported transaction as a sale rather than a purchase. This amendment is being filed to correct and restate the transaction code and footnote in their entirety. All other information set forth in the December 10, 2018 Form 4 remains correct.